Literature DB >> 34088751

Screening for Colorectal Cancer in the United States: Correlates and Time Trends by Type of Test.

Jean A Shapiro1, Ashwini V Soman2, Zahava Berkowitz2, Stacey A Fedewa3, Susan A Sabatino2, Janet S de Moor4, Tainya C Clarke5, V Paul Doria-Rose4, Erica S Breslau4, Ahmedin Jemal3, Marion R Nadel2.   

Abstract

BACKGROUND: It is strongly recommended that adults aged 50-75 years be screened for colorectal cancer. Recommended screening options include colonoscopy, sigmoidoscopy, CT colonography, guaiac fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), or the more recently introduced FIT-DNA (FIT in combination with a stool DNA test). Colorectal cancer screening programs can benefit from knowledge of patterns of use by test type and within population subgroups.
METHODS: Using 2018 National Health Interview Survey (NHIS) data, we examined colorectal cancer screening test use for adults aged 50-75 years (N = 10,595). We also examined time trends in colorectal cancer screening test use from 2010-2018.
RESULTS: In 2018, an estimated 66.9% of U.S. adults aged 50-75 years had a colorectal cancer screening test within recommended time intervals. However, the prevalence was less than 50% among those aged 50-54 years, those without a usual source of health care, those with no doctor visits in the past year, and those who were uninsured. The test types most commonly used within recommended time intervals were colonoscopy within 10 years (61.1%), FOBT or FIT in the past year (8.8%), and FIT-DNA within 3 years (2.7%). After age-standardization to the 2010 census population, the percentage up-to-date with CRC screening increased from 61.2% in 2015 to 65.3% in 2018, driven by increased use of stool testing, including FIT-DNA.
CONCLUSIONS: These results show some progress, driven by a modest increase in stool testing. However, colorectal cancer testing remains low in many population subgroups. IMPACT: These results can inform efforts to achieve population colorectal cancer screening goals. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34088751      PMCID: PMC8338800          DOI: 10.1158/1055-9965.EPI-20-1809

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  28 in total

1.  Correlates of self-reported colorectal cancer screening accuracy in a multi-specialty medical group practice.

Authors:  Arica White; Sally W Vernon; Jan M Eberth; Jasmin A Tiro; Sharon P Coan; Peter N Abotchie; Anthony Greisinger
Journal:  Open J Epidemiol       Date:  2013-02

2.  Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-10-06       Impact factor: 25.391

3.  National Center for Health Statistics Data Presentation Standards for Proportions.

Authors:  Jennifer D Parker; Makram Talih; Donald J Malec; Vladislav Beresovsky; Margaret Carroll; Joe F Gonzalez; Brady E Hamilton; Deborah D Ingram; Kenneth Kochanek; Frances McCarty; Chris Moriarity; Iris Shimizu; Alexander Strashny; Brian W Ward
Journal:  Vital Health Stat 2       Date:  2017-08

4.  Effectiveness and Cost of Organized Outreach for Colorectal Cancer Screening: A Randomized, Controlled Trial.

Authors:  Ma Somsouk; Carly Rachocki; Ajitha Mannalithara; Dianne Garcia; Victoria Laleau; Barbara Grimes; Rachel B Issaka; Ellen Chen; Eric Vittinghoff; Jean A Shapiro; Uri Ladabaum
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

5.  Patterns of colorectal cancer test use, including CT colonography, in the 2010 National Health Interview Survey.

Authors:  Jean A Shapiro; Carrie N Klabunde; Trevor D Thompson; Marion R Nadel; Laura C Seeff; Arica White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-04-06       Impact factor: 4.254

6.  Accuracy of self-reported reason for colorectal cancer testing.

Authors:  Jan M Eberth; Sally W Vernon; Arica White; Peter N Abotchie; Sharon P Coan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

7.  Diagnostic colonoscopy following a positive fecal occult blood test in community health center patients.

Authors:  David T Liss; Tiffany Brown; Ji Young Lee; Marjorie Altergott; David R Buchanan; Anne Newland; Jessica N Park; Sarah S Rittner; David W Baker
Journal:  Cancer Causes Control       Date:  2016-05-26       Impact factor: 2.506

8.  Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis.

Authors:  Douglas A Corley; Christopher D Jensen; Virginia P Quinn; Chyke A Doubeni; Ann G Zauber; Jeffrey K Lee; Joanne E Schottinger; Amy R Marks; Wei K Zhao; Nirupa R Ghai; Alexander T Lee; Richard Contreras; Charles P Quesenberry; Bruce H Fireman; Theodore R Levin
Journal:  JAMA       Date:  2017-04-25       Impact factor: 56.272

9.  Vital Signs: Colorectal Cancer Screening Test Use - United States, 2018.

Authors:  Djenaba A Joseph; Jessica B King; Nicole F Dowling; Cheryll C Thomas; Lisa C Richardson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-03-13       Impact factor: 17.586

10.  Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population.

Authors:  Theodore R Levin; Douglas A Corley; Christopher D Jensen; Joanne E Schottinger; Virginia P Quinn; Ann G Zauber; Jeffrey K Lee; Wei K Zhao; Natalia Udaltsova; Nirupa R Ghai; Alexander T Lee; Charles P Quesenberry; Bruce H Fireman; Chyke A Doubeni
Journal:  Gastroenterology       Date:  2018-07-19       Impact factor: 22.682

View more
  2 in total

1.  Persistent Disparities in Colorectal Cancer Screening: A Tell-Tale Sign for Implementing New Guidelines in Younger Adults.

Authors:  Po-Hong Liu; Nina N Sanford; Peter S Liang; Amit G Singal; Caitlin C Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-09-02       Impact factor: 4.090

2.  Sociodemographic correlates of colorectal cancer screening completion among women adherent to mammography screening guidelines by place of birth.

Authors:  Deeonna E Farr; Leslie E Cofie; Alison T Brenner; Ronny A Bell; Daniel S Reuland
Journal:  BMC Womens Health       Date:  2022-04-21       Impact factor: 2.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.